Contact

Halcyon Spur Home About Services Treatment Primer Risks & Safety Research & Policy Contact Independent treatment context Ibogaine and 5-MeO-DMT Treatment: Questions Answered A careful starting point for understanding two high-interest, high-risk psychedelics: what is being studied, what remains uncertain, and why safety cannot be treated as an afterthought. Neither substance is an approved medical treatment. This resource is for context, not for self-treatment or medical decision-making. Start with the evidence, the legal context, and the risks—not the promise. A practical orientation Interest is not the same as established care. Ibogaine and 5-MeO-DMT are attracting clinical, commercial, and policy attention because short dosing models may matter for difficult conditions. That attention exists alongside serious unresolved questions about safety, evidence quality, access, and regulation. On this page Starting point Ibogaine 5-MeO-DMT Safety questions Common questions Featured guide What are ibogaine and 5-MeO-DMT? Ibogaine is a psychoactive alkaloid associated with Tabernanthe iboga , a plant used in Bwiti traditions in Central Africa. Its pharmacology is complex and not fully understood. Modern interest has focused largely on substance use disorders, especially opioid use disorder, while the substance remains unapproved and highly restricted in many jurisdictions. 5-MeO-DMT is a short-acting, highly potent psychedelic tryptamine. It is commonly discussed in relation to synthetic formulations under investigation for treatment-resistant depression, anxiety, and possibly addiction, usually alongside structured psychological support. The basic pharmacology of 5-MeO-DMT helps explain why duration can be brief without making the experience simple or low-risk. Keep three ideas separate Traditional use, observational reports, and early clinical trials are different kinds of evidence. None should be used to erase the need for medical, psychiatric, or legal caution.

Reach us through the channels we publish.